学术论文: |
1. Liu G, Zhang Z, Wu Y, Feng J, Lan Y, Dong D, Liu Y, Yuan H, Tai G, Li S, Ni W. Anti-PD-L1 antibody reverses the immune tolerance induced by multiple MUC1-MBP vaccine immunizations by increasing the CD80/PD-L1 ratio, resulting in DC maturation, and decreasing Treg activity in B16-MUC1 melanoma-bearing mice. Int Immunopharmacol. 2023 Aug; 121:110487. doi: 10.1016/j.intimp.2023.110487. Epub 2023 Jun 24. PMID: 37364328. 2. Jie J, Liu G, Feng J, Huo D, Wu Y, Yuan H, Tai G, Ni W. MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3. Int J Mol Sci. 2022 Sep 17;23(18):10887. doi: 10.3390/ijms231810887. PMID: 36142800; PMCID: PMC9501507. 3. Liu Y, Zhang Z, Sang Q, Zhang Y, Jiang M, Zhou H, Wang J, Zhang N, Wu X, Zhou J, Ni W, Yuan H, Tai G. Recombinant MUC1-MBP fusion protein combined with CpG2006 vaccine induces antigen-specific CTL responses through cDC1-mediated cross-priming mainly regulated by type I IFN signaling in mice. Immunol Lett. 2022 May;245:38-50. doi: 10.1016/j.imlet.2022.04.002. Epub 2022 Apr 9. PMID: 35405170. 4. Wang J, Liu Y, Ni W, Wu X, Zhou J, Zhang Z, Zhou H, Zhang N, Jiang M, Sang Q, Yuan H, Tai G. TRAF6-overexpressing dendritic cells loaded with MUC1 peptide enhance anti-tumor activity in B16-MUC1 melanoma-bearing mice. Int Immunopharmacol. 2022 Jun;107:108667. doi: 10.1016/j.intimp.2022.108667. Epub 2022 Mar 4. PMID: 35255300. 5. Zhang Z, Zhou H, Liu Y, Ren J, Wang J, Sang Q, Lan Y, Wu Y, Yuan H, Ni W, Tai G. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model. Int Immunopharmacol. 2021 Dec;101(Pt A):108173. doi: 10.1016/j.intimp.2021.108173. Epub 2021 Oct 1. PMID: 34607233. |